255 related articles for article (PubMed ID: 25281033)
1. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
Peng L; Zhou Y; Ye X; Zhao Q
Tumour Biol; 2015 Feb; 36(2):643-54. PubMed ID: 25281033
[TBL] [Abstract][Full Text] [Related]
2. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
Shameem R; Lacouture M; Wu S
Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
Qi WX; Huang YJ; Yao Y; Shen Z; Min DL
PLoS One; 2013; 8(6):e65166. PubMed ID: 23785409
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
Shameem R; Lacouture M; Wu S
Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
[TBL] [Abstract][Full Text] [Related]
6. Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.
Garcia CA; Wu S
Cancer Invest; 2016 Nov; 34(10):521-530. PubMed ID: 27791402
[TBL] [Abstract][Full Text] [Related]
7. Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015 Apr; 15(4):477-86. PubMed ID: 25665062
[TBL] [Abstract][Full Text] [Related]
8. Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis.
Ramirez-Fort MK; Case EC; Rosen AC; Cerci FB; Wu S; Lacouture ME
Am J Clin Oncol; 2014 Jun; 37(3):266-71. PubMed ID: 23241507
[TBL] [Abstract][Full Text] [Related]
9. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
Shameem R; Hamid MS; Wu S
Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors.
Choueiri TK; Je Y; Sonpavde G; Richards CJ; Galsky MD; Nguyen PL; Schutz F; Heng DY; Kaymakcalan MD
Ann Oncol; 2013 Aug; 24(8):2092-7. PubMed ID: 23658373
[TBL] [Abstract][Full Text] [Related]
11. Metabolic complications with the use of mTOR inhibitors for cancer therapy.
Sivendran S; Agarwal N; Gartrell B; Ying J; Boucher KM; Choueiri TK; Sonpavde G; Oh WK; Galsky MD
Cancer Treat Rev; 2014 Feb; 40(1):190-6. PubMed ID: 23684373
[TBL] [Abstract][Full Text] [Related]
12. Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis.
Abdel-Rahman O; Fouad M
Future Oncol; 2015; 11(1):79-90. PubMed ID: 25572784
[TBL] [Abstract][Full Text] [Related]
13. Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors.
Kaymakcalan MD; Je Y; Sonpavde G; Galsky M; Nguyen PL; Heng DY; Richards CJ; Choueiri TK
Br J Cancer; 2013 Jun; 108(12):2478-84. PubMed ID: 23736025
[TBL] [Abstract][Full Text] [Related]
14. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis.
Gomez-Fernandez C; Garden BC; Wu S; Feldman DR; Lacouture ME
Eur J Cancer; 2012 Feb; 48(3):340-6. PubMed ID: 22206873
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin: biological function and target for novel anticancer agents.
Borders EB; Bivona C; Medina PJ
Am J Health Syst Pharm; 2010 Dec; 67(24):2095-106. PubMed ID: 21116000
[TBL] [Abstract][Full Text] [Related]
16. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.
Trivedi ND; Armstrong S; Wang H; Hartley M; Deeken J; Ruth He A; Subramaniam D; Melville H; Albanese C; Marshall JL; Hwang J; Pishvaian MJ
Cancer Med; 2021 Mar; 10(6):1944-1954. PubMed ID: 33638305
[TBL] [Abstract][Full Text] [Related]
18. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
Nozawa M; Ohzeki T; Tamada S; Hongo F; Anai S; Fujimoto K; Miki T; Nakatani T; Fukasawa S; Uemura H
Int J Clin Oncol; 2015 Aug; 20(4):790-5. PubMed ID: 25342378
[TBL] [Abstract][Full Text] [Related]
19. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
Lo Muzio L; Arena C; Troiano G; Villa A
Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626
[TBL] [Abstract][Full Text] [Related]
20. Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Crit Rev Oncol Hematol; 2013 Oct; 88(1):30-41. PubMed ID: 23830806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]